Which factor is listed as contributing to escalating expenditures by including the introduction of new pharmaceutical treatments?

Which factor is listed as contributing to escalating expenditures by including the introduction of new pharmaceutical treatments?

• A. Technology
• B. Chronic disease
• C. New pharmaceutical treatments
• D. Administrative costs

Answer: (C)

Introducing new pharmaceutical treatments tends to push overall expenditures upward because these drugs often come with high upfront prices, and there may be limited or no cheaper generics initially. New medications also frequently require ongoing therapy, specialist administration, and additional monitoring or diagnostic tests, all of which add to total costs. The costs embedded in research, development, and patent protection allow manufacturers to set premium prices until alternatives (like biosimilars or generics) become available. While other factors like technology, chronic disease burden, and administrative expenses influence spending, the factor that explicitly accounts for the rise tied to new drug introductions is the presence of these new pharmaceutical treatments themselves.

Introducing new pharmaceutical treatments tends to push overall expenditures upward because these drugs often come with high upfront prices, and there may be limited or no cheaper generics initially. New medications also frequently require ongoing therapy, specialist administration, and additional monitoring or diagnostic tests, all of which add to total costs. The costs embedded in research, development, and patent protection allow manufacturers to set premium prices until alternatives (like biosimilars or generics) become available. While other factors like technology, chronic disease burden, and administrative expenses influence spending, the factor that explicitly accounts for the rise tied to new drug introductions is the presence of these new pharmaceutical treatments themselves.